Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase

小剂量阿替普酶治疗下肢深静脉血栓

• 批准号: 7593114
• 负责人: mcdonald k horne
• 金额: $ 0.5万
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7593114
• 关键词: Alteplase; Anticoagulation; Chronic; Clinical Trials; Coagulation Process; Cytolysis; Daily; Deep Vein Thrombosis; Dose; Enrollment; Excision; Goals; Hemorrhage; Injection of therapeutic agent; Left; Lower Extremity; Patients; Pelvis; Peripheral; Pharmaceutical Preparations; Postphlebitic Syndrome; Protocols documentation; Reporting; Resolution; Risk; Safety; Serious Adverse Event; Symptoms; Testing; Thrombolytic Therapy; Thrombosis; Thrombus; Treatment Protocols; Veins; Venous; Week; day; thrombolysis

Patients with deep vein thrombosis of the lower extremities andor pelvis are eligible for this protocol if their thrombosis has been symptomatic for no more than 14 days and if their bleeding risk is very low. They are hospitalized for 3-7 days for up to 4 daily injections of rtPA directly into their thrombi. Simultaneously they receive anticoagulation, which is continued for 6 months. Since the last report we have enrolled 4 patients, for a total of 11. Extensive thrombolysis had been achieved with low doses of alteplase in every patient, and there have been no serious adverse events. The protocol is approved for 21 patients.

如果下肢和/或骨盆深静脉血栓形成的患者出现血栓症状不超过14天并且出血风险非常低，则有资格参加本方案。他们住院3-7天，每天最多4次将rtPA直接注射到他们的血栓中。同时，他们接受抗凝治疗，持续6个月。 自上次报告以来，我们招募了4例患者，共计11例。 在每例患者中，使用低剂量阿替普酶均实现了广泛的溶栓，且未发生严重不良事件。该方案已获批用于21例患者。